Gill Michelle A, Welliver Robert C
The University of Texas Southwestern Medical Center at Dallas, Division of Pediatric Infectious Diseases, Department of Pediatrics, 5323 Harry Hines Boulevard, Dallas, TX 75235-9063, USA.
Expert Opin Biol Ther. 2009 Oct;9(10):1335-45. doi: 10.1517/14712590903287499.
Respiratory syncytial virus (RSV) is the most important respiratory viral pathogen of infancy. The only unequivocally effective pharmacological compound for the management of RSV infection is palivizumab, a monoclonal antibody against the fusion protein of RSV. Recently, motavizumab, a similar but more potent monoclonal antibody, has been developed and tested against palivizumab.
In this review, we summarize data comparing the safety and efficacy of the two monoclonal antibodies in prevention of RSV infection. Other therapeutic options also are discussed.
We reviewed all published articles listing motavizumab or palivizumab in the title or keywords.
RESULTS/CONCLUSION: In a large comparative clinical trial for which peer review is pending, motavizumab proved noninferior to palivizumab for prevention of RSV-related hospital admission in infants with underlying conditions placing them at high risk for hospitalization after RSV infection. In this trial, motavizumab in comparison to palivizumab significantly reduced the severity of illness among those infants hospitalized with RSV infection, as well as the number of outpatient lower respiratory infections caused by RSV. Safety profiles of each of the two compounds were excellent. Based on these data, motavizumab should eventually replace palivizumab in the prevention of RSV infection.
呼吸道合胞病毒（RSV）是婴儿期最重要的呼吸道病毒病原体。用于管理RSV感染的唯一明确有效的药物是帕利珠单抗，一种针对RSV融合蛋白的单克隆抗体。最近，莫他珠单抗，一种类似但更有效的单克隆抗体，已被开发并与帕利珠单抗进行对比测试。
在本综述中，我们总结了比较这两种单克隆抗体预防RSV感染的安全性和有效性的数据。还讨论了其他治疗选择。
我们检索了所有标题或关键词中列出莫他珠单抗或帕利珠单抗的已发表文章。
结果/结论：在一项尚待同行评审的大型对比临床试验中，对于预防因潜在疾病而在RSV感染后有高住院风险的婴儿的RSV相关住院，莫他珠单抗被证明不劣于帕利珠单抗。在该试验中，与帕利珠单抗相比，莫他珠单抗显著降低了RSV感染住院婴儿的疾病严重程度，以及RSV引起的门诊下呼吸道感染数量。两种化合物的安全性均良好。基于这些数据，莫他珠单抗最终应会在预防RSV感染方面取代帕利珠单抗。
